Dendritic, Water‐Soluble, and Nonaggregated Axially Substituted Silicon Phthalocyanine as Potential Endometrial Anticancer Agent-Reference-Cited by-同舟云学术

Dendritic, Water‐Soluble, and Nonaggregated Axially Substituted Silicon Phthalocyanine as Potential Endometrial Anticancer Agent

Published:2024-08-15 Issue: Volume: Page:
ISSN:0268-2605
Container-title:Applied Organometallic Chemistry
language:en
Short-container-title:Applied Organom Chemis

Author:

Keles Turgut¹^ORCID,Seyhan Gökçe²^ORCID,Biyiklioglu Zekeriya³^ORCID,Kolci Kübra⁴⁵,Reis Rengin⁴,Barut Burak²^ORCID

Affiliation:

1. Central Research Laboratory Application and Research Center Recep Tayyip Erdoğan University Rize Türkiye

2. Faculty of Pharmacy, Department of Biochemistry Karadeniz Technical University Trabzon Türkiye

3. Faculty of Science, Department of Chemistry Karadeniz Technical University Trabzon Türkiye

4. Faculty of Pharmacy, Department of Toxicology Acibadem Mehmet Ali Aydinlar University Istanbul Türkiye

5. Faculty of Pharmacy, Department of Toxicology Yeditepe University Istanbul Türkiye

Abstract

ABSTRACTIn this work, dendritic, water‐soluble, and nonaggregated axially substituted silicon phthalocyanines (EA‐TD‐Si and EA‐TD‐SiQ) were synthesized and characterized. Then, the supercoiled pBR322 plasmid DNA damage properties of EA‐TD‐Si and EA‐TD‐SiQ were examined using agarose gel electrophoresis without light irradiation. In addition, the cytotoxicity and phototoxicity of EA‐TD‐Si and EA‐TD‐SiQ on human endometrium adenocarcinoma (HEC‐1B) cells were investigated using an MTT assay. The results indicated that EA‐TD‐SiQ had high photodamage properties via singlet oxygen depending on the light dose, while EA‐TD‐Si did not show any DNA damage without light. In addition, EA‐TD‐SiQ had higher phototoxic effects than EA‐TD‐Si on HEC‐1B cells according to the MTT assay. These results revealed the potential of EA‐TD‐SiQ to be used as a PDT agent in endometrial cancer.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/aoc.7699

Reference29 articles.

1. World Cancer Research Fund International Endometrial Cancer Statistics accessed April 01 2024 https://www.wcrf.org/cancer‐trends/endometrial‐cancer‐statistics/.

2. C.Bosch Solanes Photodynamic Therapy as an Alternative to Progestogens in Endometrial Cancer Grade 1A G1: Multicenter Clinical Analysis(2022).

3. Nanocarrier-based targeting of metabolic pathways for endometrial cancer: Status and future perspectives

4. Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives

5. The Anticancer Effects of Radachlorin‐Mediated Photodynamic Therapy in the Human Endometrial Adenocarcinoma Cell Line HEC‐1‐A;Kim S. M.;Anticancer Research,2017